These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1153148)

  • 21. [Evaluation of the climacteric symptomatology modifications and clinical-instrumental parameters in women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and in surgical menopause treated with estrogen replacement therapy. Part I].
    Savoca S; D'Agosta S; Lombardo G
    Minerva Ginecol; 2007 Jun; 59(3):205-14. PubMed ID: 17576399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
    Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
    Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Episodic secretion of LH and FSH after ovariectomy. Secretory patterns in response to estrogen and progesterone.
    Wallach EE; DeCherney AH; Russ D; Duckett G; Garcia CR; Root AW
    Obstet Gynecol; 1973 Feb; 41(2):227-33. PubMed ID: 4684207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Transcutaneous estradiol treatment in the climacteric].
    Pedersen OD; Jensen HK
    Ugeskr Laeger; 1990 Sep; 152(36):2561-4. PubMed ID: 2402844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
    Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
    Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis.
    Luciano AA; Turksoy RN; Carleo J
    Obstet Gynecol; 1988 Sep; 72(3 Pt 1):323-7. PubMed ID: 2970029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of progestins on vasomotor flushes.
    Schiff I
    J Reprod Med; 1982 Aug; 27(8 Suppl):498-502. PubMed ID: 7131442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reply to Dr. Edwin B. McDaniel. Exaggerated claims of depo-provera safety.
    Minkin SF
    Women Health; 1981; 6(1-2):125-9. PubMed ID: 6223451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of large doses of medroxyprogesterone acetate (MPA) on urinary estrogen levels and serum levels of cortisol T4 LH and testosterone in patients with advanced cancer.
    Sadoff L; Lusk W
    Obstet Gynecol; 1974 Feb; 43(2):262-7. PubMed ID: 4359078
    [No Abstract]   [Full Text] [Related]  

  • 30. Symptomatology and hormone profile of menopausal Nigerians.
    Akingbade OA; Bolarinwa AF; Subbarao VV
    Afr J Med Med Sci; 1990 Jun; 19(2):133-7. PubMed ID: 2115729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaginal cytologic evaluation as a practical link between hormone blood levels and tumor hormone dependency in exclusive medroxyprogesterone treatment of recurrent or metastatic endometrial adenocarcinoma.
    Bonte J; Decoster JM; Ide P
    Acta Cytol; 1977; 21(2):218-24. PubMed ID: 266331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes.
    Albrecht BH; Schiff I; Tulchinsky D; Ryan KJ
    Am J Obstet Gynecol; 1981 Mar; 139(6):631-5. PubMed ID: 7211966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in the ratio of bioactive to immunoreactive serum luteinizing hormone during vasomotor flushes and hormonal therapy in postmenopausal women.
    Chang SP; Shoupe D; Kletzky OA; Lobo RA
    J Clin Endocrinol Metab; 1984 May; 58(5):925-9. PubMed ID: 6323519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Frequency of symptoms of the climacteric syndrome].
    Hernández-Valencia M; Córdova-Pérez N; Basurto L; Saucedo R; Vargas C; Vargas A; Ruiz M; Manuel L; Zárate A
    Ginecol Obstet Mex; 2010 Apr; 78(4):232-7. PubMed ID: 20939230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The climacteric.
    Studd J; Chakravarti S; Oram D
    Clin Obstet Gynaecol; 1977 Apr; 4(1):3-29. PubMed ID: 558077
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of medroxyprogesterone acetate on serum levels of LH, FSH, cortisol, and estrone in patients with endometrial carcinoma.
    Vesterinen E; Backas NE; Pesonen K; Stenman UH; Laatikainen T
    Arch Gynecol; 1981; 230(3):205-11. PubMed ID: 6787991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasomotor symptoms, serum estrogens, and gonadotropin levels in surgical menopause.
    Aksel S; Schomberg DW; Tyrey L; Hammond CB
    Am J Obstet Gynecol; 1976 Sep; 126(2):165-9. PubMed ID: 961757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new combination of conjugated equine oestrogens and medroxyprogesterone for treatment of climacteric complaints.
    Cullberg G; Knutsson F; Mattsson LA
    Maturitas; 1984 Jul; 6(1):55-63. PubMed ID: 6088950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival.
    Ertz-Archambault NM; Rogoff LB; Kosiorek HE; Ernst BJ; Anderson KS; Pockaj BA; Gray RJ; Northfelt DW
    Support Care Cancer; 2020 May; 28(5):2139-2143. PubMed ID: 31402403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A multicenter comparison of veralipride versus placebo in the vasomotor flushes of menopause. An evaluation of the prolonged effect].
    Boulot P; Viala JL
    Rev Fr Gynecol Obstet; 1988 Dec; 83(12):823-7. PubMed ID: 3064254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.